Page last updated: 2024-09-04

cyc 202 and Cholangiocarcinoma

cyc 202 has been researched along with Cholangiocarcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Harada, K; Sasaki, M; Sato, Y; Takahashi, K; Yamamura, M	1

Other Studies

1 other study(ies) available for cyc 202 and Cholangiocarcinoma

Article	Year
The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma. Oncology reports, 2020, Volume: 43, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Animals; Bile Duct Neoplasms; Biomarkers, Tumor; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Mice; Middle Aged; Neoplasm Staging; Phosphorylation; Protein Kinase Inhibitors; Roscovitine; Survival Analysis; Xenograft Model Antitumor Assays	2020

Article

Year

The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.

Oncology reports, 2020, Volume: 43, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Animals; Bile Duct Neoplasms; Biomarkers, Tumor; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Mice; Middle Aged; Neoplasm Staging; Phosphorylation; Protein Kinase Inhibitors; Roscovitine; Survival Analysis; Xenograft Model Antitumor Assays

2020